Seminara P, Franchi F, Mulieri M, D'Amelio R, Codacci Pisanelli G, Aronne T, Manfredi D
Tumori. 1987 Feb 28;73(1):69-73. doi: 10.1177/030089168707300114.
The chemosensitivity of 26 non-pretreated colorectal carcinomas (primary tumors and/or colorectal metastases) was studied by an in vitro antimetabolic assay, which evaluates the interference of drugs on the incorporation of 3H-thymidine and 3H-uridine in short-term cultures of human tumors. Our results correlate with the response rate obtained in clinical studies with monochemotherapy and justify the possibility of a future prospective study using individually tailored chemotherapy regimens. Doxorubicin-analogues, with an overall in vitro efficacy in 16.0% and 14.3% for 4-epidoxorubicin (epi-DX) and 4-deoxydoxorubicin (deo-DX), respectively, seem to deserve a modest role in the treatment of colorectal cancer, provided that a careful selection of patients is performed. Variability in anthracycline activity is indeed evident, also in our study, in relation to the different neoplastic picture of the various patients.
通过体外抗代谢测定法研究了26例未经预处理的结直肠癌（原发性肿瘤和/或结直肠转移瘤）的化学敏感性，该方法评估药物对人肿瘤短期培养中3H-胸腺嘧啶核苷和3H-尿苷掺入的干扰。我们的结果与单药化疗临床研究中的缓解率相关，并证明了未来使用个体化化疗方案进行前瞻性研究的可能性。阿霉素类似物，4-表阿霉素（表柔比星）和4-脱氧阿霉素（去氧柔红霉素）的总体体外疗效分别为16.0%和14.3%，如果对患者进行仔细选择，似乎在结直肠癌治疗中可发挥一定作用。在我们的研究中，与不同患者的不同肿瘤情况相关，蒽环类药物活性的变异性确实很明显。
